The European Fund for Strategic Investments (EFSI) advancing Israel’s Pluristem 50 million Euros to fund 50% of its pioneering regenerative PLX cell therapy platform. Pluristem’s treatment has saved six critically ill Israeli coronavirus patients (see previously).
EU finance for Israeli coronavirus treatment
This entry was posted in Economy & Business. Bookmark the permalink.